Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

Ilka Decker, MD MS, Oluchi C. Ukaegbu, MD, Stacey A. Goodman, MD MS, Daniel J. Lenihan, MD, Rebecca R Hung, MD, Adetola A. Kassim, MD MS, Shelton L. Harrell, MSN, ACNP-BC, Kevin McDonagh, MD, Sharon E. Phillips, MSPH, Kyle T Rawling, Samuel M Rubinstein, MD, Tarsheen K. Sethi, MD MS, Robert F Cornell, MD MS

Blood (2015) 126 (23): 1841.

https://doi.org/10.1182/blood.V126.23.1841.1841

Published: 2015

Journal Articles

In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant

Robert F Cornell, MD MS, Jade E Jones, Claudio A. Mosse, Heidi Chen, Laura Dugger, Salil Goorha, Wichai Chinratanalab, Brian Engelhardt, Stacey A. Goodman, MD MS, John P Greer, Shelton Lacy, Adetola A. Kassim, MD MS, Kevin McDonagh, Bipin N. Savani, MD, Salyka Sengsayadeth, Madan Jagasia

Blood (2015) 126 (23): 5493.

https://doi.org/10.1182/blood.V126.23.5493.5493

Published: 2015

Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD

Blood (2015) 126 (23): 377.

https://doi.org/10.1182/blood.V126.23.377.377

Published: 2015

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc): Long-Term Survivors Show Continued Improvement of Function and Skin with Stability in the Lungs.

Peter McSweeney, MD, Daniel Furst, MD, Leslie Crofford, MD, Kevin McDonagh, MD, Keith Sullivan, MD, Mayes Maureen, MD, Nelson Lee, MD, Theodore Gooley, Ph.D., Jan Storek, MD, PhD, Leona Holmberg, MD, PhD, C.S. Chen, MD, PhD, Mark Wener, MD, Julie Lee, RN, Gretchen Henstorf, CCRC, Muneer Abidi, MD, Philip Mease, MD, Richard Nash, MD

Blood (2004) 104 (11): 149.

https://doi.org/10.1182/blood.V104.11.149.149

Published: 2004

NARROW

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc): Long-Term Survivors Show Continued Improvement of Function and Skin with Stability in the Lungs.

Email alerts

ASH Publications

American Society of Hematology

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc): Long-Term Survivors Show Continued Improvement of Function and Skin with Stability in the Lungs.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only